Side-by-side · Research reference
CagrilintidevsOvagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BTheoreticalHUMAN-REVIEWED2/42 cited
Ovagen
Khavinson Bioregulator · Ovarian
OvarianTarget tissue
Di/Tri-peptidePeptide length
AnimalEvidence tier
Oral / SQ · Protocol varies
01Mechanism of Action
Parameter
Cagrilintide
Ovagen
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
Ovarian tissue chromatin complexes
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration
Feedback intact?
Yes — acts via physiological amylin pathways
Presumed physiological — Khavinson peptides described as regulatory, not replacement
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
Ovagen
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Frequency
Once weekly (subcutaneous)Bailey 2026
Long-acting formulation.
Once daily or cyclical (10–20 days per month)
Cyclical protocols common in Khavinson bioregulator tradition.
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Theoretical / Russian-tradition
Duration
26–52 weeks in trialsYamauchi 2026
4–12 weeks per cycle
Khavinson protocols typically 1–3 months; repeat cycles as needed.
Route
Subcutaneous injectionBailey 2026
Oral (capsule) or subcutaneous
Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.
Standard dose
—
10–20 mg / day (oral) or 1–2 mg SQ
Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
Ovagen
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
04Side Effects & Safety
Parameter
Cagrilintide
Ovagen
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Reported adverse events
—
None documented in indexed literature
Theoretical hormonal effects
—
Ovarian stimulation — monitor for estrogen-sensitive conditions
Injection site reaction
—
Possible mild erythema (SQ route)
Long-term safety
—
Unknown — no PubMed-indexed RCTs
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Ovagen
- ·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- ·Pregnancy
Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
Ovagen
- ·History of estrogen-sensitive tumors (monitor)
- ·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- ·Endometriosis or fibroids (estrogen-responsive conditions)
05Administration Protocol
Parameter
Cagrilintide
Ovagen
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
—
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
Ovagen
— no documented stacks